PlainPill

Cagrilintide

The short answer. There isn't much data on Cagrilintide yet — 32 mentions, 11 with a clear outcome — so treat these numbers as anecdotal. It is most often used for appetite: 100% of 8 reports say that improved. It is well studied — 9 meta-analyses on PubMed. The most common complaint is fatigue. It is not an approved supplement and carries real risks.

What users report
82%helped11 reports · few reports
9 helped2 mixed0 didn't help

From 32 mentions in total — the rest didn't say how it went and aren't counted.

Clinical research
AStrong research base
9
meta-analyses
15
RCTs
101
papers
High-risk compound. Peptides are not approved as supplements, carry serious and sometimes irreversible risks, are banned in competitive sport and may be restricted where you live. Nothing here is a recommendation to use it.

What Cagrilintide does, according to users

Of the people who reported each effect, the share who said it got better.

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

AStrong research base

3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 9 meta-analyses on PubMed ↗ · 15 randomized trials ↗

BMJ · 2024 · Meta-analysis / systematic review
Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis

Conclusion: GLP-1RAs are efficacious in treating adults with type 2 diabetes. Compared with the placebo, tirzepatide was the most effective GLP-1RA drug for glycaemic control by reducing haemoglobin A1c and fasting plasma glucose concentrations. GLP-1RAs also significantly improved weight management for type 2 diabetes, with CagriSema performing the best for weight loss. The results prompt safety concerns for GLP-1RAs, especially with high dose administration, regarding gastrointestinal adverse events.

PubMed 38286487 ↗
BMJ · 2026 · Meta-analysis / systematic review
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis

Conclusion: Obesity drugs produce variable weight loss at one year, with larger benefits generally accompanied by greater harms and discontinuation. Most agents do not improve quality of life meaningfully and few show cardiovascular benefits. Decisions in clinical practice should consider trade-offs between benefits and harms within the context of shared decision making.

PubMed 42419792 ↗

Dosage people report

We don't list doses for unapproved research compounds. Dosing should only come from a doctor or pharmacist.

Reported side effects

How often each side effect came up across all reports.

fatigue ×3appetite loss ×1depressive episode ×1

What users say

First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.

“Cagri was a game changer for me. I added 1mg and thats been more than enough.”
HelpedRead the discussion ↗
“Every needs to be aware of the severe fatigue that shows up for some ppl, for me it almost landed me in a depressive episode.”
MixedRead the discussion ↗
“Also using Cagri / Tirz to cut while weight training 4 x per week and logging calories / macros. Working great for me, I’m maintaining weight but my body composition is changing for the better.”
HelpedRead the discussion ↗
“I recently mixed semaglutide with Cagrillintide and it turned murky. I still injected it and it was fine, actually better than fine it worked great.”
HelpedRead the discussion ↗
Read more Cagrilintide reviews →
Top discussions (5)

Cagrilintide compared

Other options for appetite

Sources

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate